AMAG Pharmaceuticals, Inc. provided earnings guidance for the fourth quarter and full year of 2016. The company expects total GAAP revenue to be between $149 million and $154 million for the fourth quarter of 2016, which includes Makena net product sales of between $96 million and $99 million, Feraheme and MuGard net product sales of between $25 million and $27 million, and CBR service revenue of approximately $28 million. AMAG expects fourth quarter 2016 total non-GAAP revenue to be between $150 million and $155 million, which reflects a $1.4 million purchase accounting adjustment related to CBR deferred revenue. AMAG expects 2016 total GAAP revenue to be between $529 million and $534 million, which includes Makena net product sales of between $333 million and $336 million, Feraheme and MuGard net product sales of between $96 million and $98 million, and CBR service revenue of approximately $100 million. AMAG expects 2016 non-GAAP revenue to be between $546 million and $551 million, which reflects a $17 million purchase accounting adjustment related to CBR deferred revenue. For the year the company excepts GAAP revenue to be between $620 million - $670 million. Non-GAAP revenue to be between $625 million - $675 million. GAAP net income to be between $19 million - $60 million. GAAP operating income to be between $103 million - $173 million. Non-GAAP Adjusted EBITDA to be between $270 million - $340 million.